Starpharma technology improves anti-cancer drug 40-fold
29 October, 2012 by Dylan Bushell-EmblingAnimal trials of Starpharma's (ASX:SPL) dendrimer-docetaxel chemotherapy product show the formulation is potentially far more effective at targeting tumours than the conventional formula.
AusBiotech 2012 special feature: Found in translation
29 October, 2012 by Tim DeanHere are five ways that are currently being discussed that could transform the commercialisation of medical research in Australia.
Abraxane performs well in metastatic melanoma
26 October, 2012 by Dylan Bushell-EmblingSpecialised Therapeutics Australia (STA) has revealed some positive results from a phase III trial of nanoparticle chemotherapy Abraxane in metastatic melanoma.
Pharmaxis' Bronchitol to get NHS listing in UK
26 October, 2012 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has received the final approval required to have its Bronchitol cystic fibrosis treatment cleared for reimbursement by the UK National Health Service.
Have you registered for biotech’s industry event of the year?
25 October, 2012 by AusBiotechProminent biotechnology individuals from across Australia and around the world will join the conference for agenda-setting programs, world-class networking and partnering opportunities, and over 150 industry-leading speakers in more than 30 sessions.
Agenix opens new avenues with diagnostics deal
25 October, 2012 by Dylan Bushell-EmblingAgenix (ASX:AGX) has arranged to license a diagnostic device platform from Tyrian Diagnostics in a share swap deal.
R&D Tax Incentive remains untouched as tax reform stalls
25 October, 2012 by Tim DeanThe government’s Business Tax Working Group has failed to reach agreement on how to fund a cut in corporate tax, leaving the R&D Tax Incentive as is.
Avexa's antibiotic storms lab tests
24 October, 2012 by Dylan Bushell-EmblingAvexa's (ASX:AVX) anti-bacterial compound AVX13616 has performed well in lab tests conducted by licensee Valevia Pharmaceuticals.
Australian biotechs significantly outperforming ASX and Nasdaq
24 October, 2012 by Tim DeanThe Australian life science index is known for its volatility, but over the past decade it has outperformed the All Ordinaries and the Nasdaq by considerable margins.
Biota cleared to merge with Nabi
23 October, 2012 by Dylan Bushell-EmblingBiota Holdings (ASX:BTA) has been cleared to merge with Nabi Biopharmaceuticals after shareholders in both companies approved the deal.
Latest journal features AusBiotech 2012, tech transfer and more…
23 October, 2012 by AusBiotechAusBiotech is pleased to announce that the bumper special edition of AusBiotech’s journal, Australasian Biotechnology, is now published, featuring a sneak peek at next week’s industry conference of the year, AusBiotech 2012, as well as a feature on tech transfer and biotechnology in Asia.
Test strip earnings boost UBI revenue
22 October, 2012 by Dylan Bushell-EmblingUniversal Biosensors (ASX:UBI) boosted its Q3 revenue by 50% and slashed its cash outflow, thanks to contributions from its two coagulation test strip partnerships.
Bioniche launches canine cancer product in NA
19 October, 2012 by Dylan Bushell-EmblingBioniche Life Sciences (ASX:BNC) has launched its first canine cancer product, Immunocidin, in the US and Canadian markets.
Bluechiip enters sample tracking tie-up
19 October, 2012 by Dylan Bushell-EmblingBluechiip (ASX:BCT) has partnered with Swiss laboratory systems developer Inpeco, agreeing to explore jointly developing Inpeco products with integrated Bluechiip tracking chips.
Allied Healthcare's CardioCel used in first non-trial procedure
18 October, 2012 by Dylan Bushell-EmblingAllied Healthcare (ASX:AHZ) has reached a milestone with its CardioCel cardiovascular patch product, announcing its first surgical use outside of clinical trials.
